Pharmaceutical compositions, and a method of stabilizing pharmaceuticalcompositions having clevidipine, or any pharmaceutically acceptable saltthereof,as the active ingredient is described. The method includes the slowing down orinhibiting of the oxidation pathway of clevidipine. This can be accomplishedbyreducing the amount the pharmaceutical composition is exposed to oxygen and/orlight during the, manufacturing and storing processes. According to thismethod,oxygen must be removed or replaced, or light must be sufficiently blocked suchthat light energy cannot reach the active ingredient of the composition, or isreduced to a level that the light-induced oxidation reaction convertingclevidipineto H324nS is minimized, such that the total detectable level of H324nS in agivencomposition sample does not exceed about 0.2% on a weight-by-weight basis.
